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ABSTRACT 
 
INTRODUCTION:  Multi-drug resistant tuberculosis (MDR-TB) poses a great threat to the 
eradication of TB. In the US, MDR-TB is faced with inadequate diagnostic tools and long and 
expensive treatment regimens. Therefore, preventing the disease is the key to saving lives and 
resources. Social and behavioral variables play a big part in this prevention. It is important to 
determine the social factors that may lead to MDR-TB in order to set up prevention programs and 
more efficient treatment regimens.  
AIM:  This study was conducted to ascertain the social determinants of MDR-TB in the US 
between the years of 2005 and 2009 to better equip public health officials to deal with this 
growing threat.  
METHODS: This study used the Centers for Disease Control and Prevention (CDC) Online 
Tuberculosis Information System (OTIS) database to find associations between certain social 
variables and MDR-TB. The variables that were tested were whether or not the individual had 
lived in a correctional facility for the past year; HIV status; homelessness; whether or not the 
individual had an occupation; and whether the individual was foreign-born or US-born. An 
unadjusted odds ratio (OR) was calculated to find this association. The variables were then 
stratified with age; sex; race; age and race; age and sex; and age, sex, and race to see whether or 
not the strata were confounders.  
RESULTS: The variables of having lived in a correctional facility and homelessness were found 
to be associated with MDR-TB. However, all of the strata were found to be confounders for this 
relationship. Having HIV and being US-born were not found to be associated with MDR-TB. All 
of the strata for HIV were found to be confounders.  But for place of birth, stratifying by age, sex, 
and both age and sex were not confounders. The rest of the strata were. The OR for occupation 
versus MDR-TB was almost at 1, meaning that those with a job and those without a job had 
almost equal odds of having MDR-TB. Effect modification was present for the strata in all 
variables, meaning that the risk of having MDR-TB varied with each different age, sex, and racial 
group.  
   
DISCUSSION: Results from this study showed which variables were more likely to be 
associated with MDR-TB in the US between the years of 2005 and 2009. However, when 
compared to the literature that exists, the results showed that more research needs to be done to 
properly ascertain this relationship. Using this study, public health officials can identify which 
populations to focus prevention efforts on.  
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CHAPTER 1 
INTRODUCTION 
 The eradication of tuberculosis (TB) has been made much more difficult with the 
emergence of multidrug-resistant TB (MDR-TB). The World Health Organization 
(WHO) estimated 650,000 cases of MDR-TB around the world in 2010 (Walter, Strong 
et al. 2012). The actual number of cases may be a lot greater since surveillance for MDR-
TB is inadequate because of the lack of laboratory resources around the world for testing 
drug sensitivity. This is a problem that not only affects developing nations, but is a threat 
to the control of TB in developed nations.   
Public Health Importance  
MDR-TB is a growing threat to the United States (US).  In 2011, it was reported 
by the Centers for Disease Control and Prevention (CDC) that 9.2% of TB cases in the 
US were resistant to one first-line TB drug and 1.3% was resistant to more than one drug 
(ALA 2013). The number of MDR-TB cases in the US is increasing each year. This study 
will help to determine associations between MDR-TB and some of its social and 
behavioral risk factors. It is important to look at the social risk factors for MDR-TB 
because they help us better understand the behaviors of individuals that lead to the 
disease and how these behaviors can be altered.  The CDC tracks many of these variables 
in their Online Tuberculosis Information System (OTIS) Database.  Literature also shows 
these variables to be the ones associated with higher rates of MDR-TB elsewhere in the 
world. Therefore, it would be ideal to focus on how these variables are associated with 
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MDR-TB. The aim is to find the variables associated with MDR-TB in order to set up 
prevention programs for the future. This study hopes to be the first step in that process.  
 
 
1a. Study Objective 
 Developed nations, such as the United States, have set procedures and resources 
that help control tuberculosis.  However, MDR-TB is a threat to these TB control 
measures.  This study will look at the social determinants of MDR-TB compared to those 
of TB in the United States from 2005 to 2009. This association has not been one that has 
been explored before.  The study will look at the association of MDR-TB with the 
variables of occupation; place of birth; HIV status; homelessness in the past year; and 
whether or not the person lived in a correctional facility and stratify them with age, sex, 
race, and a combination of the three. These specific variables are tracked annually by the 
CDC. If associations are found, public health officials can focus on specific behaviors 
related to these variables and set up programs that better prevent MDR-TB. 
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1c. Research Question 
Is there an association between specific risk factors and the rates of multidrug resistant 
tuberculosis in the United States? 
 
Can the analysis of the data provide a model to predict multidrug resistant rates in the 
United States? 
 
How can the answers to the previous two questions be used to formulate interventions 
and possibly come up with solutions to the problem of multidrug resistant tuberculosis in 
the United States? 
 
 
 
 
4 
 
CHAPTER 2 
LITERATURE REVIEW 
2a. Background of TB 
 Tuberculosis (TB) is a disease that is caused by the bacterium Mybacterium 
tuberculosis. It usually manifests as a respiratory illness, but can present in other areas of 
the body as well such as joints, kidneys, and the brain. If it is not treated properly, it can 
be fatal.  
 TB is a highly contagious disease that is spread through the air. One must inhale 
the infectious droplets to become infected. However, TB is not spread through person-to-
person physical contact, sharing bodily fluids, or touching infected surfaces.  
 Tuberculosis is an ancient disease that can be traced back to the time before 
humans.  The genus Mycobacterium is thought to have originated more than 150 million 
years ago during the Jurassic period (Daniel 2006). Reports show that an early 
predecessor of M. tuberculosis may have infected early hominids as far back as 3 million 
years ago in present East Africa. However, modern strains of M. tuberculosis are thought 
to have originated about 20,000-15,000 years ago (Daniel 2006). Knowing the mutation 
rate of M. tuberculosis, scientists have concluded that a lot of present diversity among the 
strains of this bacterium came about between 2,500-1,000 years ago. Egyptian mummies 
from more than 5,000 years ago show skeletal abnormalities typically associated with 
tuberculosis. The art from this era also depicts the ailments associated with tuberculosis. 
However, there are very limited written records of tuberculosis in ancient Egypt. The 
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Bible also mentions tuberculosis using the ancient Hebrew word “schachepheth.” 
Peruvian mummies show archaeological evidence of tuberculosis in the Americas. 
During the middle ages, though written records of tuberculosis became hard to find, the 
phenomenon of the “royal touch” became widespread in Europe.  The royal touch 
consisted of monarchs touching individuals with tuberculosis in hopes of curing them 
(Daniel 2006).  
During the Renaissance, knowledge of tuberculosis began to change. René 
Théophile Hyacinthe Laennec clarified the pathogenesis of the disease, unified the 
concept of pulmonary and extrapulmonary TB, and described the physical symptoms of it 
(Daniel 2006). Laennec’s exposition pioneered the modern understanding of tuberculosis.  
During this era, tuberculosis had reached epidemic levels across Europe and society 
began romanticizing the disease.  People with TB were said to be interesting and 
melancholy. Many authors of the time, such as Emily Brontë, described their tuberculosis 
characters as, “young and fresh.” Many other examples of this romanticism of TB can be 
found in the works of Charles Dickens and Lord Byron and in the descriptions of 
important figures of the time.  
On March 24, 1882, the history of tuberculosis changed when Hermann Heinrich 
Robert Koch made his famous presentation, Die Aetiologie der Tuberculose. His 
presentation identified his famous postulates, known as the Koch-Henle postulates, which 
are still the standard for identifying infectious disease causality. In 1909, pediatrician 
Clemens Freiherr von Pirquet introduced the term “latent tuberculosis,” when he 
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published a study of tuberculin reactions that showed positive tuberculin reactions in 
children who did not have symptoms of tuberculosis. Charles Mantoux introduced the use 
of needles and syringes to inject tuberculin into the skin. Florence Seibert was the one 
who developed purified protein derivative (PPD) in 1908 in fundamentally the same form 
it is used today. PPDs were used to establish the commonality of latent TB infection in 
the United States. In 1921, Albert Calmette and Camille Guérin developed a vaccine for 
tuberculosis called the BCG (Bacille Calmette-Guérin). Over the next decade, the vaccine 
was used to protect hundreds of thousands of children from TB infection. However, BCG 
was not widely used in the United States, where treatment of latent infection was more 
emphasized (Daniel 2006). The 1950s brought about the biggest advances in tuberculosis 
with the development of treatment drugs. In 1950, the British Journal of Tuberculosis and 
Diseases of the Chest reported the first case of streptomycin as treatment. The first oral 
anti-tuberculosis drug, Isoniazid, followed in 1952, with rifamycin in 1957. Tuberculosis 
control entered a new era with the introduction of these treatments. The next section will 
describe the symptoms of TB, along with the treatments in the new era.  
 Once a person becomes infected with the TB bacteria, they develop one of two 
conditions: latent TB infection and active TB disease. Latent TB infection is when M. 
tuberculosis lives in the body without causing any symptoms. The infected person is not 
infectious and cannot spread TB during this phase and is said to have Latent TB Infection 
(LTBI). But, the TB bacteria can become active at any time and cause active TB disease. 
When a person has active TB disease, the M. tuberculosis is actively spreading through 
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their body.  The site of the infection determines the symptoms that a person experiences. 
For pulmonary TB, the symptoms include a bad cough lasting three weeks or more, chest 
pain, weight loss, weakness or fatigue, loss of appetite, blood or sputum in the cough, 
chills, fever, and night sweats.  
There are many ways to diagnose tuberculosis. The most common is a TB skin 
test, often referred to as a TST or PPD. It is performed by injecting a small amount of the 
liquid tuberculin under the skin in the forearm. The patient must then wait between 48-72 
hours to have their area checked by a health professional. The healthcare worker checks 
to see the reaction the person has had. The area is checked for a hard raised area and then 
measure the diameter of the area, if present. Whether or not the result is positive depends 
on the size of the induration. An induration greater than 10 mm is indicative of a positive 
diagnosis. The diagnosis is influenced by a person’s age and their risk for contracting TB. 
A positive test means the person either has active or latent TB infection and further tests 
need to be done to determine which. A negative skin test means that the person’s body 
did not react to the test, and it is unlikely that they are infected with TB (CDC, 2012). 
However, in some cases, these people may still be infected with TB and must be 
diagnosed using their symptoms. These people are referred to as anergic.  
 Tuberculosis may also be diagnosed with a blood test, called interferon-gamma 
release assays or IGRAs. This test is a blood test that measures how the immune system 
reacts to the TB bacteria. Like the TSTs, a positive test means the person is likely 
infected with active or latent TB and further tests need to be done to determine exactly 
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which one. A negative IGRA means it is not likely the person is infected with TB disease. 
IGRAs are preferred to TSTs in the case that a patient has received bacille Calmette-
Guérin (BCG), which is a TB vaccine, or a patient is not able to return to have their TST 
evaluated (CDC, 2012).  
 Treatment for tuberculosis is based on the type of TB a patient has. The goal of 
latent TB treatment is to prevent the patient from developing active TB disease. Latent 
TB infections are treated with one of four regimens suited to meet their needs. All four of 
the regimens include different variations of the medications isoniazid (INH), rifampin 
(RIF), and rifapentine (RPT) for various durations (CDC, 2012).  
 Treatment for active tuberculosis is more extreme since these people have 
significantly greater numbers of TB bacteria in their bodies. Currently, there are 10 drugs 
on the market that are approved for the treatment of TB. However, the main four that are 
used as the front-line drugs are isoniazid (INH), rifampin (RIF), ethambutol (EMB), and 
pyrazinamide (PZA). The treatment regimens last 6-9 months, with the first two months 
known as the initial phase, followed by a continuation phase lasting from 4 to 7 months. 
It is imperative that patients complete their drug regimens because failing to do so can 
lead to re-infection or drug resistance (CDC, 2012).  
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2b. Background of MDR-TB 
MDR-TB is caused by strains of Mybacterium tuberculosis that are resistant to at 
least isoniazid and rifampicin, two of the most powerful first-line drugs to combat TB 
(Migliori, D'Arcy Richardson et al. 2009). Molecular epidemiological techniques have 
shown that the M. tuberculosis strain known as the “Beijing,” is responsible for MDR-TB 
outbreaks in countries with lower rates of TB, such as the United States (Drobniewski, 
Balabanova et al. 2005).  In addition to the great global threat that the disease poses, it 
can also lead to the more deadly extensively drug-resistant TB (XDR-TB). XDR-TB is 
caused by Myobacteria that meet the same requirements as MDR-TB, but are also 
resistant to any fluroquinolone and to at least 1 of 3 anti-TB injectable drugs: 
capreomycin, amikacin, or kanamycin (Migliori, D'Arcy Richardson et al. 2009).  As is 
to be expected, the mortality for both of these forms of TB is high.  Among XDR-TB 
patients, mortality rates are similar to the pre-antibiotic era (Ershova, Kurbatova et al. 
2012).  
 MDR-TB and XDR-TB can occur for many different reasons. First, it may be due 
to the providers.  They may prescribe inadequate drug regimens for patients, whether it 
be not enough doses, not enough drugs, the incorrect drugs, or a too short treatment time. 
The second reason may come down to the patients. They may not follow their drug 
regimens as prescribed. Third, the drugs used to treat TB may not be of good quality 
(Migliori, D'Arcy Richardson et al. 2009).  
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 The second reason listed above, patients not following their drug regimens as 
prescribed, will be the focus of this study. Finding out the factors that hinder patients 
from correctly taking their medication is imperative. Once those factors are known, steps 
can be taken to help in those situations and prevention programs can be set up. As will be 
explained later, prevention is a key factor in the fight against MDR-TB in this nation.  
 MDR-TB and XDR-TB are either primary or acquired. Primary drug resistance 
takes place when MDR-TB or XDR-TB is directly transmitted from one individual to 
another. Acquired drug resistance may happen through the incorrect use of TB drugs. 
(Migliori, D'Arcy Richardson et al. 2009).  
 The issue of drug resistance to TB was first realized shortly after streptomycin 
was introduced in 1944. The first reported death from a drug-resistant strain of TB was 
reported by the British Medical Research Council in 1948. This led to the discovery in 
the late 1940s that combination therapy with both streptomycin and para-aminosalycilic 
acid was an effective treatment for the emerging drug-resistant strains.  However, the 
duration of this treatment regimen was markedly long. Beginning in 1952, the 
introduction of INH, RIF, EMB, and PZA kept the problem in check until the 1980s. In 
the early 1990s, however, there began several outbreaks of MDR-TB, particularly among 
Human Immunodeficiency Virus (HIV)-infected patients, that brought this problem back 
to the forefront as a major global public health issue (Nguy, Shui et al. 2009).  The most 
well-known of these outbreaks was a cluster that took place in one Florida hospital and 
three New York City hospitals from 1990 to 1992. These outbreaks had mortality rates 
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between 72% and 83% among HIV positive patients. These outbreaks led to an overhaul 
in the way MDR-TB was reported on in the country and allowed for population-based 
analysis of the disease (Migliori, D'Arcy Richardson et al. 2009). 
 Multidrug resistant tuberculosis is diagnosed using drug susceptibility testing 
(DST). DST is a difficult procedure to perform and standardize because it requires the 
knowledge of the origins of the drug resistance and the conditions surrounding it; potency 
and stability of drugs in the lab; antimycobacterial activity of the drugs in different 
testing mediums; and reading interpretation of the results. From start to finish, the test 
takes one month to complete and may only be done once a TB diagnosis has been 
established. It also requires a live growing organism. DST must also be done for first- 
and second-line drugs separately (CDC 2010). DST is a long, complicated, and expensive 
process and usually only given to patients of high priority (Manjourides, Lin et al. 2012). 
Therefore, prevention is key when it comes to MDR-TB.  
 
2c. Treatment of MDR-TB 
 Treatment of MDR-TB is an arduous and expensive process.  It can take up to two 
years to treat with drugs that are less potent and more toxic than regular TB drugs 
(Jenkins, Zignol et al. 2011). The drug regimen for treating drug-resistant TB depends on 
the exact drugs the patient is resistant to. The drugs that can be used as part of the 
treatment regimen are isoniazid (INH); rifampin (RIF); pyrazinamide (PZA); ethambutol 
(EMB); streptomycin (SM); ciprofloxacin or ofloxacin or moxifloxacin or gatifloxacin 
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(FQ); injectable agents like SM or kanamycin or amikacin or capreomycin or viomycin; 
and second-line drugs such as rifabutin, ethionamide, prothionamide, para-amino 
salicylic acid, D-cycloserine and thiacetazone. Treatment regimens can include anywhere 
from three to many of these drugs at a time and last anywhere from six months to over 
two years (Ahmad, Suhail et al. 2010). Patients must be closely monitored to ensure they 
follow the treatment regimen exactly. The outcome of the treatment depends on the type 
of drug-resistance, the availability of the previously listed drugs, and the patient’s 
adherence to the therapy (Migliori, D'Arcy Richardson et al. 2009).  
 In extreme cases, surgical resection of the infected lung tissue has been used as 
treatment.  This treatment method is only used in cases with severe drug resistance with a 
high probability of medication therapy failing, localized disease with good postoperative 
expectations for lung function, and ample activity of TB drugs to ensure proper healing 
of the surgery stump.  Surgical measures should only be offered after medication 
treatment has been tried for at least three months (Migliori, D'Arcy Richardson et al. 
2009).  
 
2d. Risk Factors for MDR-TB 
 There are many different risk factors for multi-drug resistant TB. A survey done 
by Casal, et. al. identified immigration, aging, HIV infection, population mobility, living 
in communities, and drug abuse as possible factors in Western European countries (Casal, 
Vaquero et al. 2005).   
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HIV 
When tuberculosis drugs became available in the 1950s, the disease began a steady 
decline in Western countries.  However, TB re-emerged with the advent of human 
immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) 
(Breathnach, de Ruiter et al. 1998). Shenoi et al. estimated that as of 2009, there were 12-
14 million people coinfected with HIV and M. tuberculosis. They also stated that TB is 
the most common opportunistic infection among HIV patients (Shenoi, Heysell et al. 
2009).  The CDC states that as of July 2012, a quarter of all HIV/AIDS deaths can be 
attributed to TB (2012).  HIV lowers an individual’s ability to fight off infection, making 
them more susceptible to not only regular TB, but MDR-TB and XDR-TB as well.  
HIV/AIDS has  been associated with the malabsorption of  TB drugs, which may 
contribute to higher rates of drug-resistance (Andrews, Shah et al. 2010). A cross-
sectional, country-wide study done in Estonia found that HIV-infected patients are three 
times more likely to develop extensively drug-resistant tuberculosis than those not 
infected with HIV (Kliiman and Altraja 2009). In Ukraine, it was found that HIV patients 
are at a higher risk for developing multidrug-resistant TB during their first occurrence of 
TB, which differs from non-HIV patients (Shenoi, Sheela et al. 2009).  
Patients infected with HIV are not only more likely to develop MDR-TB; they also 
have higher rates of mortality from the disease.  Between the years 1993 and 2007, 26 
deaths occurred from XDR-TB in the U.S. Out of these deaths, 21 were confirmed HIV-
positive cases (Migliori, D'Arcy Richardson et al. 2009). Mortality rates in North 
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America have ranged from 70-90% with a median survival time ranging from 4-6 weeks 
from diagnosis to death (Kelleher, Coakley et al. 1996).  
One of the biggest issues facing the coinfection of multidrug-resistant TB and HIV is 
the inability to get a rapid TB diagnosis and then subsequently determine drug 
susceptibility. The patients must wait for a diagnosis, and in the meantime, they not only 
spread disease but they also are given inadequate treatment. In South Africa, most 
patients with XDR-TB die before their results come back and even before they have had 
a chance to be tested for drug resistance (Shenoi, Sheela et al. 2009).  This issue is mainly 
one in developing nations, but can affect the developed world in areas where adequate 
TB diagnostic tools do not exist.  
Co-infection of MDR/XDR TB and HIV can also have a great impact on the HIV 
epidemic. Shenoi et al. listed ten ways drug-resistant TB can affect HIV:  
1) higher risk of drug-resistant TB compared to patients not infected with HIV; 
2) higher mortality rates for co-infected individuals; 
3) potential side effects from combing secondline TB drugs and antiretrovirals (ARVs);  
4) hospital-related transmission of drug-resistant TB to HIV patients; 
5) risk to healthcare workers dealing with HIV patients; 
6) strain on national TB and DOT programs; 
7) demand exceeding the amount of available laboratory services and specialized 
treatment referral;  
8) competition for resources between TB and HIV programs; 
9) greater stigma for co-infected patients; 
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10) general undoing of gains made in HIV epidemic from ARVs (Shenoi, Sheela et al. 
2009).  
The evidence for an association between MDR-TB and HIV is strong. However, no 
study has measured the association within the same parameters and the same time frame 
that this study will.  
 
 
Previous TB Infection 
A well-established risk factor of multidrug-resistant TB is prior TB infection 
(Andrews, Shah et al. 2010).  One study put the rate of acquired resistant as high as 20% 
for previous cases, with 4-10% going on to develop full-fledged MDR-TB (Casal, 
Vaquero et al. 2005).  According to a study done by Tracy Dalton across Estonia, Latvia, 
Peru, the Philippines, Russia, South Africa, South Korea, Thailand, and Taiwan, a history 
of TB was the strongest risk factor for MDR-TB, with the overall value of 93.8% 
probability (Hoffner). The risk only increases the more times a person is treated for TB 
(Zhao, Xu et al. 2012) or the longer their treatment regimen lasts (Migliori, D'Arcy 
Richardson et al. 2009). These results show the importance of programs such as directly 
observed therapy (DOT), where patients are monitored while they take TB medications to 
ensure the regimen is being followed correctly and having the desired outcomes. DOT 
helps cure most cases and prevents the development of chronic cases, which can go on to 
become drug resistant (Casal, Vaquero et al. 2005). Many of the variables studied in this 
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thesis are not only risk factors for MDR-TB; they are also risk factors for regular TB. 
This, as this section states, is itself a risk factor for MDR-TB. 
 
US-born versus Foreign-born   
Global migration and travel have had an immense impact on TB in the United States.  
It was reported that between 2001 and 2008, 54.6% (62,364) of the new TB cases in the 
U. S. were diagnosed among foreign-born patients. Of this, 249 cases were MDR-TB 
cases (Liu, Painter et al. 2012). More recent statistics state that foreign-born cases are 
now responsible for 80% of the MDR-TB cases in the U.S. (Migliori, D'Arcy Richardson 
et al. 2009). Table 1 provides the exact statistics from 1993. A recent study reported that 
active pulmonary TB was diagnosed in 7.0% of refugees and immigrants in the United 
States when these same patients had smear-negative diagnoses before arrival to the 
country (Liu, Painter et al. 2012). Therefore, it can be concluded from this study that at 
least some immigrants and refugees are acquiring the disease upon entering the country. 
Finding this association is important because then, the reasons behind the association can 
be explored.  
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Table 2.1 Incidence of MDR-TB in the United States among new cases according to 
place of birth, 1993-2007 
 New MDR-TB Cases 
Year Total United States-born (%) Foreign-born (%) 
1993 407 301 (74) 103 (26) 
1994 353 238 (67) 110 (33) 
1995 254 169 (67) 85 (33) 
1996 207 105 (51) 101 (49) 
1997 155 76 (49) 79 (51) 
1998 132 55 (42) 76 (58) 
1999 127 39 (31) 88 (69) 
2000 120 38 (32) 82 (68) 
2001 118 34 (29) 84 (71) 
2002 130 36 (28) 94 (72) 
2003 92 24 (26) 68 (74) 
2004 102 26 (25) 76 (75) 
2005 98 19 (19) 78 (81) 
2006 94 17 (18) 77 (82) 
2007 98 20 (20) 78 (80) 
Adapted from : (Migliori, D'Arcy Richardson et al. 2009) 
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Hospitalization  
Some studies have shown hospitalization as a risk factor for MDR-TB. A study 
conducted in South Africa by Andrews, Shah, et al concluded that a prolonged hospital 
stay is associated with a 3-fold increase in the risk of contracting MDR-TB (Andrews, 
Shah et al. 2010). Another recent study suggested that MDR-TB patients that were 
treated with first-line drugs were responsible for the majority of TB spread in a 
tuberculosis ward of the hospital (Escombe, Moore et al. 2008).  Gandhi, Weissman et al. 
used social network analysis to study XDR-TB and concluded that rather than an 
outbreak starting from a single patient, there is a high degree of interconnectedness 
among hospital patients. The study also stated that the long delay in diagnosing XDR-TB 
patients contributed to transmission since it gave unrecognized patients time and 
opportunity to infect others in congregation areas.  (Gandhi, Weissman et al. 2013).  
 
 
Poverty 
As stated earlier, homelessness has been associated with MDR-TB and XDR-TB. The 
homeless live in poor conditions and are usually malnourished from reduced access to 
food. They also have reduced access to healthcare. This prolongs their period of 
infectiousness, increasing their risk of transmission to their peers. The homeless also have 
higher rates of defaulting from their treatment, thus increasing their risk for drug-resistant 
TB (Migliori, D'Arcy Richardson et al. 2009). Poverty is also linked to higher rates of 
incarceration. Prisons have  reported higher rates of drug-resistant strains of tuberculosis 
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due to overcrowding and the inability to isolate the resistant cases (Migliori, D'Arcy 
Richardson et al. 2009).  
 
Race 
Many studies have linked race to multidrug resistant TB.  A study conducted in Texas 
stated that US-born blacks are more likely than US-born whites to not only have drug-
resistant forms for tuberculosis; they are also more likely to have a lot of the risk factors 
for MDR-TB (Serpa, Teeter et al. 2009). The study went on to explain that 
socioeconomic characteristics are linked to race and therefore explain the disparity in TB 
rates.  
 
Age  
Age may be a risk factor for MDR-TB. A disproportionate number of older adults 
are affected by all forms of TB due the weakening of their immune systems with age. 
They are also more likely to be afflicted with illness such as diabetes mellitus, renal 
disease, and silicosis, which increases the risk of progressing from LTBI to active TB 
disease. Certain medications taken by older adults, such as corticosteroids and transplant 
suppression drugs, also accelerate the progression to active disease (Pratt, Winston et al. 
2011). Also, just being older and being around peers who are more susceptible to TB 
increases risk. With increased risk of TB comes increased risk of drug resistant forms.  
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The literature shows that all of the previously listed variables may be associated 
with higher rates of MDR-TB. Therefore, it was important for this study to include as 
many of them as possible in data analysis and test the associations for the sample 
population. The next chapter will explain the methodology of this data analysis.  
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CHAPTER 3 
METHODS 
 The main objective of this study was to find the association between certain social 
determinants and multidrug-resistant tuberculosis in the United States. The variables that 
were examined were whether or not the patient lived in a correctional facility at the time 
of diagnosis; HIV status; homelessness; whether or not the patient had an occupation; and 
place of birth (US-born or foreign born), all between the years of 2005 and 2009. Each 
variable was cross-tabulated with MDR-TB to find the crude odds ratio (OR). Each crude 
OR was then each stratified by age; sex; race; age and race; age and sex; and age, sex, 
and race to find if any of the strata were confounders between the variable in question 
and MDR-TB.  
 
3a. Data Sources 
 All of the data were obtained from the CDC Online Tuberculosis Information 
System (OTIS). OTIS contains information on verified TB cases as reported to the CDC 
by state health departments, the District of Columbia, and Puerto Rico from 1993 to 
2010. The data is extracted using the CDC national TB surveillance system. This 
database is updated annually and includes data for 26 variables that can be cross-
stratified. Users can obtain charts, graphs, and tables and extract the data for the available 
variables.  
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3b. Study Population 
 The study population was the US population, including all 50 states and the 
District of Columbia. All races/ethnicities, genders, and ages were incorporated.  
 
 
3c. Statistical Analysis 
 The OTIS database does not allow for raw data to be extracted. Therefore, it was 
impossible to use statistical analysis software to examine the data. Instead, each variable 
was cross-tabulated with MDR-TB and then stratified by race/ethnicity, sex, and age. 
First, each association was stratified by age; then sex, then race independently; then by 
both age and race; then by both age and sex, and lastly by age, sex, and race. The 
race/ethnic groups the data were classified in are Non-Hispanic Whites; Hispanics; Non-
Hispanic Blacks or African Americans; and Other, which included Non-Hispanic Native 
Americans and Non-Hispanic Asians and/or Pacific Islanders. The sexes were classified 
into male and female. The ages were grouped by 0-24 years of age and 25 and above.  
For all of the variables, only the Yes/No results were used. Therefore, only the variables 
that could be put into a 2x2 Yes/No table were able to be included. All of the 
indeterminate and not reported data were ignored. The stratification was done in OTIS, 
after which the data were transferred to Microsoft Excel (version 2010). From there, the 
data were put into 2x2 tables to calculate odds ratios and Mantel-Haenszel odds ratios to 
find associations between the variables and MDR-TB and to decipher if any of the 
variables were confounded by the different stratifications of age, sex, and race.  
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CHAPTER 4 
RESULTS 
 
 The main purpose of this study was to find the social determinants of multidrug-
resistant tuberculosis in the United States. To find the association, if any, between certain 
variables and MDR-TB, the Mantel-Haenszel odds ratio (ORmh) was calculated. Below 
are the results for each of the following variables as tested against MDR-TB: 
1) Whether or not the patient was in a correctional facility 
2) HIV Status 
3) Homelessness 
4) Whether or not the patient had an occupation 
5) Place of birth 
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Correctional Facility vs. MDR-TB 
 
Table 4.1 Results of Correctional Facility vs. MDR-TB 
EXPOSURE ORMH EFFECT 
MODIFICATION 
Crude OR = 1.757 --------------- --------------- 
Age 1.793  Negative Confounding Present 
Sex 1.581  Positive Confounding Present 
Race 1.436  Positive Confounding Present 
Age, Race 1.442  Positive Confounding Present 
Age, Sex 1.612  Positive Confounding Present 
Age, Sex, Race 1.361  Positive Confounding Present 
 
 These calculations were testing the association between living in a correctional 
facility and having MDR-TB. The crude OR for this association is 1.757, meaning that 
those that resided in a correctional facility in the past year have a 75% increase in the 
odds of developing MDR-TB than those who did not reside in a correctional facility in 
the past year. However, as this association was further stratified, it showed different 
results. Age was shown to be a negative confounder for the association between living in 
a correctional facility and having MDR-TB.  Negative confounding means that the OR is 
falsely lowered. Further stratification by sex; race; age and race; age and sex; and age, 
sex, and race showed that these strata are positive confounders for the association 
between living in a correctional facility and having MDR-TB. Positive confounding 
means that the OR is falsely elevated. All of the strata showed effect modification; 
meaning that the different groups (i.e. different age groups, different racial groups, males 
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and females) had different risk estimates for the association between living in a 
correctional facility and having MDR-TB.  
 
 
HIV Status vs. MDR-TB 
 
Table 4.2 Results of HIV Status vs. MDR-TB 
EXPOSURE ORMH EFFECT 
MODIFICATION 
Crude OR = 0.764 --------------- --------------- 
Age 0.692  Positive Confounding No Effect Modification 
Sex 0.741  Positive Confounding Present 
Race 0.569  Positive Confounding Present 
Age, Race 0.522  Positive Confounding Present 
Age, Sex 0.678  Positive Confounding Present 
Age, Sex, Race 0.511  Positive Confounding Present 
  
The crude OR for the association between HIV and MDR-TB showed a surprising 
result. It showed that those with HIV were about 25% less likely to have MDR-TB than 
those without HIV. Each stratification showed positive confounding, meaning that when 
stratified with those variables, the ORs were falsely elevated and should have been lower. 
Effect modification was present in all of the strata except age, meaning that the risk 
estimates for age were the same but were different for all of the other strata.  
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Homeless vs. MDR-TB 
 
Table 4.3 Results of Homeless vs. MDR-TB 
EXPOSURE ORMH EFFECT 
MODIFICATION 
Crude OR = 1.157 --------------- --------------- 
Age 1.086  Positive Confounding Present 
Sex 1.052  Positive Confounding Present 
Race 0.864  Positive Confounding Present 
Age, Race 0.811  Positive Confounding Present 
Age, Sex 1.004  Positive Confounding Present 
Age, Sex, Race 0.783  Positive Confounding Present 
 
 This set of calculations tested the association between being homeless and having 
MDR-TB. The crude OR showed the homeless are 15% more likely to have MDR-TB 
than those that are not homeless. However, all of the strata showed positive confounding 
and effect modification.  
 
 
 
Occupation vs. MDR-TB 
 
Table 4.4 Results of Occupation vs. MDR-TB 
EXPOSURE ORMH EFFECT 
MODIFICATION 
Crude OR = 0.990 --------------- --------------- 
Age 1.004  Negative Confounding Present 
Sex 0.957  Positive Confounding Present 
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Race 1.050  Negative Confounding Present 
Age, Race 1.056  Negative Confounding Present 
Age, Sex 0.970  Positive Confounding Present 
Age, Sex, Race 1.030  Negative Confounding Present 
 The crude OR for the association between having an occupation and having 
MDR-TB was 0.990. Since this OR is so close to 1, it means that both groups (those with 
an occupation and those without) have almost the same odds of getting MDR-TB. The 
different strata showed various results. When this association was further stratified by 
age; race; age and race; and age, sex, and race, these strata were shown to be negative 
confounders, meaning that the OR was falsely lowered.  However, stratification by sex 
and by both age and sex showed these respective strata to be positive confounders, 
meaning they falsely elevated the OR. Effect modification was present for all of the 
strata.  
 
 
Place of Birth vs. MDR-TB 
 
Table 4.5 Results of Place of Birth vs. MDR-TB 
EXPOSURE ORMH EFFECT 
MODIFICATION 
Crude OR = 0.292 --------------- --------------- 
Age 0.299  No Confounding Present 
Sex 0.296  No Confounding Present 
Race 0.413  Negative Confounding Present 
Age, Race 0.377  Negative Confounding Present 
Age, Sex 0.299  No Confounding Present 
Age, Sex, Race 0.400  Negative Confounding Present 
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 When calculating the association between place of birth and having MDR-TB, the 
crude OR was 0.292. This means that those that were US-born were about 70% less 
likely to have MDR-TB than those that were foreign-born. When further stratified by age, 
sex, and by both age and sex, there was no confounding. Meaning that these three strata 
were not confounders in the relationship between place of birth and having MDR-TB. 
When stratifying by race; age and race; and age, sex, and race, there was negative 
confounding, showing that the OR was falsely lowered. Effect modification was once 
again present in all strata. 
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CHAPTER 5 
DISCUSSION 
 The main objective of this study was to find the social determinants of multidrug 
resistant TB in the US.  The variables that were examined and tested against the rates of 
MDR-TB were whether or not the patient was in a correctional facility; HIV status; 
homelessness; occupation; and place of birth. These variables were then stratified by 
race, sex, and age to find associations.  The specific research questions asked were: 
 
Is there a correlation between specific risk factors and the rates of multidrug resistant 
tuberculosis in the United States versus drug-treatable tuberculosis? 
 
Can the analysis of the data provide a model to predict multidrug resistant rates in the 
United States? 
 
How can the answers to the previous two questions be used to formulate interventions 
and possibly come up with solutions to the problem of multidrug resistant tuberculosis in 
the United States.  
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 Confounding is a difficult phenomenon to understand and explain. A confounding 
variable is usually related to both the independent and dependent variables, thus affecting 
the relationship between the variables. There could be several reasons why a certain 
characteristic is a confounder.  The next section will attempt to explain the disparities in 
the results as each variable was tested against MDR-TB. 
 When looking at the association between having lived in a correctional facility in 
the past year and MDR-TB, the unadjusted odds ratio showed that those who have lived 
in a correctional facility in the past year are 75% more likely to have MDR-TB than those 
who did not live in a correctional facility. A study done by Dalton et al. reinforced this 
result. The study was a prospective cohort study evaluating the prevalence and the risk 
factors of MDR-TB in eight different countries. They concluded that resistance to 
second-line injectable TB drugs was associated with imprisonment (Dalton, Cegielski et 
al.). Internationally, TB prevalence in prisons is high; as is transmission of resistant 
strains. This could be explained by prison overcrowding and the inability of these prisons 
to isolate the resistant cases (Migliori, D'Arcy Richardson et al. 2009). However, all of 
the strata were shown to be confounders for the association between living in a 
correctional facility and having MDR-TB, meaning that the MDR-TB could be due to 
either living in a correctional facility or due to age, sex, race, or a combination of the 
three. Future studies would have to control for these variables when testing the 
relationship between living in a correctional facility versus having MDR-TB.  
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 With a crude OR of 0.764, the association between HIV and MDR-TB was shown 
to be protective. Those with HIV were shown to be 25% less likely to have MDR-TB 
than those without HIV. This was surprising since most of the literature suggested the 
opposite. Some of the literature even went as far as to suggest that there is an epidemic of 
HIV and MDR-TB coinfection (Shenoi, Heysell et al. 2009). It may be that the unusual 
results that were achieved pertain only to the sample population. In a study done in the 
country of Georgia, it was found that HIV and AIDS both were not associated with the 
development of drug-resistant TB (Vashakidze, Salakaia et al. 2009). Another case-
control study about the risk factors for MDR-TB in four European countries also 
concluded that HIV status did not prove to be a statistically significant risk factor for 
MDR-TB at the European level. Suchindran et al. also state that not a single study from 
Africa showed an association between HIV and MDR-TB and that results from other 
regions were also conflicting (Suchindran, Brouwer et al. 2009).  Again, further studies 
would have to be conducted in the United States to ascertain if HIV and MDR-TB are 
associated or not.  
 When looking at the association between homelessness and MDR-TB, the results 
showed that homeless people were 15% more likely to have MDR-TB than those that 
were not homeless. Literature showed an association between being homeless and having 
XDR-TB, but not MDR-TB. However, since XDR-TB is a more severe form of MDR-
TB, the explanations for the associations can be similar. Homeless people live in poor 
conditions and are often malnourished. They have less access to healthcare and are more 
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likely to default from treatment. Homelessness is also associated with alcohol abuse, 
which has been shown by many studies to be associated with higher rates of MDR-TB 
(Migliori, D'Arcy Richardson et al. 2009). Kliiman et al. also found homelessness to be 
an independent risk factor for MDR-TB (Kliiman and Altraja 2009).  
 The unadjusted OR for the relationship between having and occupation and 
having MDR-TB was 0.990. This OR was so close to 1 that it means both groups, those 
with an occupation and those without, have about the same risk for getting MDR-TB. 
While the literature did not mention having or not having an occupation as a risk factor 
for MDR-TB, it did mention poor living conditions as a factor. Poor living conditions 
usually come about when one does not have a source of income, i.e. a job.  
 The last variable that was tested was place of birth versus MDR-TB. The crude 
OR showed that the US-born were about 70% less likely to get MDR-TB than those that 
were foreign-born. TB rates among foreign-born that have recently arrived to the US 
continue to remain very high (Liu, Painter et al. 2012). A study done in California found 
that most MDR-TB cases in the US are related to the migration of those who have 
already been infected with MDR-TB (Metcalfe, Kim et al. 2010). These results show that 
better screening procedures and treatment options should be made available for newly 
arrived persons to the US.  
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Limitations 
 There were several limitations to this study.  The main limitation was the database 
that was used. The OTIS database did not provide raw data. The lack of these data did not 
allow for full testing of association. The testing that was done had to be done by hand. 
Therefore, human error should also be taken into account. The data did not provide 
information on other social determinants such as socioeconomic status, alcohol abuse, 
hospitalization, etc.  that would have been helpful in explaining MDR-TB rates. The 
study was also limited by its use of secondary data, as opposed to primary data.  
 
Conclusions and Recommendations 
 The study tested five variables against MDR-TB to find association measures 
according to age, sex, and race. The evidence showed these three strata and combinations 
of the three to be confounders for the separate variables and MDR-TB.  
The results of the calculations and the literature showed that it is important to 
control and strive to improve the situation of MDR-TB.  Further testing of the variables 
that lead to MDR-TB should be done in the sample population and expanded populations 
to help find ways to prevent the disease. Improved treatment regimens for MDR-TB that 
include less toxic drugs, shorter treatment durations, and generally more efficient drugs 
should be developed (Walter, Strong et al. 2012).  Studying the mechanism of mutation 
to develop drugs that are more targeted to treated resistant strains of M. tuberculosis 
would help with this endeavor (Walter, Strong et al. 2012). New anti-TB drugs should be 
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developed for all forms of TB and randomized control trials should be used to evaluate 
them (Walter, Strong et al. 2012). Better ways of testing for tuberculosis should be 
established that provide faster diagnoses (Walter, Strong et al. 2012). Another factor that 
would help improve MDR-TB rates would be to increase drug resistance testing before 
treatment begins (Zhao, Xu et al. 2012). Making sure TB treatment is completed is also 
imperative. Directly observed therapy programs should be in place to ensure patients are 
completing their drug regimens. All of these suggestions would help WHO of achieving 
its goal of eradicating all forms of TB by the year 2050.  
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